USPTO issues notice of allowance for Windtree’s SERCA2A activators

USPTO issues notice of allowance for Windtree’s SERCA2A activators
Preview
来源: Pharmaceutical Technology
The activators might lead to the development of new therapies to treat heart failure. Credit: Ground Picture / Shutterstock.com.
The United States Patent and Trademark Office (USPTO) has issued a notice of allowance for Windtree Therapeutics’ patent application covering a group of SERCA2A [a key protein in the cycle of heart failure] activators with a dual mechanism.
The company stated that the family of drug candidates of SERCA2a activators has similar mechanisms of action to those of istaroxime, a first-in-class dual mechanism therapy.
Recommended Reports
USPTO issues notice of allowance for Windtree’s SERCA2A activators
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - ISB-1442 GlobalData
USPTO issues notice of allowance for Windtree’s SERCA2A activators
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - (semaglutide + GIP analogue) GlobalData
View all
It might therefore lead to the development of new therapies to treat heart failure.
Dual mechanism SERCA2a activators work by inhibiting the Na+/K+ pump [an enzyme found in the membrane of all animal cells] and activating SERCA2a.
Windtree Therapeutics noted that these product candidates are intended to be both oral and IV therapies.
They might represent both an outpatient, oral therapy for chronic heart failure and hospital discharge, and an inpatient therapy for the treatment of acute decompensated heart failure.
In April 2023, the dual mechanism SERCA2a activator class of drug candidates received a patent from the European Patent Office.
Windtree Therapeutics CEO and president Craig Fraser stated: “We are pleased to see the continued progress of our IP portfolio strategy for the dual mechanism SERCA2a activator family of drug candidates.
“The development strategy with these dual mechanism compounds is for potential ‘fast follow-on’ drug candidates that can leverage the experience with istaroxime and provide the potential added feature of oral bioavailability for use as a treatment for chronic heart failure.
“This composition of matter patent represents a key part of our plan for these assets and we look forward to the next step in the process from the USPTO.”
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。